Future Medical Device Companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies

STXS 2.910

-0.3%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: semi_infinite who wrote (38)	11/7/2006 11:34:49 PM
From: dr.praveen	of 136

Stereotaxis Announces Clearance of Stereotaxis System for Use in Neurovascular and Peripheral Applications Monday November 6, 8:00 am ET ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS - News) today announced 510(k) FDA clearance of the Niobe® magnetic navigation system for use in neurovascular and peripheral applications with the Company's family of Cronus® magnetically enabled .014" vascular guidewires. Stereotaxis had previously received FDA clearance to use the Niobe System and Cronus guidewire family in coronary vasculature procedures only. The Cronus guidewire family will now integrate with the Niobe magnetic navigation system to provide precise magnetic guidewire navigation in coronary, neurovascular and peripheral anatomy. "While we have no current plans to immediately move into peripheral and neurovascular clinical applications, this clearance provides us with the flexibility to do so at a time of our choosing," said Bevil Hogg, President and Chief Executive Officer of Stereotaxis, Inc. "We believe this latest clearance is further evidence of the broad applicability of our system to the entire body."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next